136434-34-9 (S)-Duloxetine HCl AKSci J10476
 
 
Loading Please Wait...
  J10476    AKSci Reference Standard
(S)-Duloxetine HCl
, 99% (HPLC), powder
 
(gamma-S)-N-Methyl-(1-naphthalenyloxy)-2-thiophenepropanamine hydrochloride
(+)-(S)-N-Methyl-gamma-(1-naphthyloxy)-2-thiophenepropylamine hydrochloride
(+)-N-Methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine hydrochloride
more..




IDENTITY
CAS Number:136434-34-9
MDL Number:MFCD06407958
MF:C18H20ClNOS
MW:333.88
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:99% (HPLC), powder
Spectra:LCMS, HPLC
Physical Form:White to off-white to light pink powder
Melting Point:162-172°C
Boiling Point:64-65°C (0.760mmHg)
Flash Point:9.7°C
Optical Rotation:+116.0° - +125.0° (c=1, MeOH)
Density:0.791
Long-Term Storage:Store long-term in a cool, dry place
HAZARDOUS MATERIALS INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:H2O: soluble5 mg/mL (clear solution, warmed)
Application(s):Serotonin-norepinephrine reuptake inhibitor
Form:HCl salt

REVIEW

 Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors. The antidepressant and pain inhibitory actions of duloxetine are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS. The mechanism of action of duloxetine in SUI has not been determined, but is thought to be associated with the potentiation of serotonin and norepinephrine activity in the spinal cord, which increases urethral closure forces and thereby reduces involuntary urine loss.

REFERENCES
[1]Turcotte JE, Debonnel G, de Montigny C, Hebert C, Blier P: Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001 May;24(5):511-21.
[2] Anttila S, Leinonen E: Duloxetine Eli Lilly. Curr Opin Investig Drugs. 2002 Aug;3(8):1217-21.
[3] Karpa KD, Cavanaugh JE, Lakoski JM: Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev. 2002 Winter;8(4):361-76.
[4] van Groeningen CJ, Peters GJ, Pinedo HM: Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. Eur J Cancer Clin Oncol. 1989 Jan;25(1):45-9.

GHS

Pictograms

Signal Word
Danger

Hazard Statements
H225; H301+H311+H331; H370

Precautionary Statements
P210; P233; P240; P241; P242; P243; P260; P264; P270; P271; P280; P301+P310; P303+P361+P353; P304+P340; P307+P311; P322; P330; P361; P363; P370+P378; P403+P233; P403+P235; P405; P501


Current as of April 21, 2021

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS

For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.


CATEGORIES

 APIs and Bioactives > Antidepressants


PubChem